Fever-Tree Shares Fall 6.4% Despite H1 EBITDA Beat as US Margins Weigh

Fevertree Drinks shares dropped 6.4% to 765.5p on Thursday after the premium mixer maker reported interim results for the six months to 30 June 2026. Adjusted EBITDA of £20.1 million and revenue of £184.2 million both beat forecasts, yet investors focused on weaker US margins and elevated marketing spend in the company’s key growth market. The stock moved closer to its 52-week low of 711p.

Fever-Tree H1 EBITDA £20.1m (+9%), Revenue £184.2m; US Margin Drops to 6.2%

Adjusted EBITDA rose 9% year-on-year to £20.1 million (H1 2025: £18.4 million), topping Jefferies’ £19.5 million estimate. Adjusted revenue increased 7% to £184.2 million (from £172.2 million), ahead of the broker’s £182.2 million forecast. Group adjusted EBITDA margin improved 20 basis points to 10.9%.

Regional performance showed clear divergence. US revenue grew 7% to £66.9 million (11% at constant currency). UK revenue returned to growth, up 3% to £49.5 million. Europe rose 13% (10% constant currency) to £49.6 million, and Rest of World increased 7% (5% constant currency) to £17.6 million. Total adjusted Fever-Tree brand revenue reached £183.6 million, up 8% at constant currency.

US segment adjusted EBITDA fell to £4.1 million from £5.0 million, with the margin declining to 6.2% from 8.1%. The drop reflected higher marketing investment to support the Molson Coors partnership and brand-building. Rest of Group delivered a stronger 24.5% margin. Diluted EPS rose 38% to 9.44p. The interim dividend was lifted 2% to 6.09p per share, payable 16 October 2026. Cash stood at £68 million. The company is progressing a £60 million share buyback programme.

Jefferies left its full-year 2026 revenue forecast of £400.7 million and EBITDA forecast of £50.1 million unchanged, making only a modest EPS upgrade due to a lower diluted share count from buybacks. Management confirmed full-year expectations remain in line with market consensus and noted substantial hedging of glass and aluminium costs through 2026, with broader commodity cover extending into 2028.

Sell the News: Fever-Tree Drops as Thin US Margins (6.2%) Overshadow Beat

Investors treated the results as a classic “sell the news” event. The numbers met or modestly exceeded estimates but offered no material upgrade to full-year forecasts. Thin US margins (6.2%) and the deliberate step-up in marketing spend in Fever-Tree’s largest and most strategically important market overshadowed solid growth elsewhere. The market remains focused on whether US expansion can deliver durable profitability rather than just top-line gains. The 52-week range of 711p–973p highlights ongoing sensitivity to the US story.

Fever-Tree US Transition Under Molson Coors Drives 11% Growth; Non-Tonic Hits 47% of Sales

Fever-Tree continues its transition in the US under the Molson Coors distribution partnership, which began in early 2025. The partnership has driven market-share gains and an 11% constant-currency revenue rise, but near-term profitability has been diluted by higher marketing and the profit-sharing structure. Non-tonic products now account for 47% of group sales, supporting diversification. The company remains highly cash-generative and has returned substantial capital via buybacks while maintaining a progressive dividend. Input-cost hedging provides earnings visibility against geopolitical and commodity volatility.

Fever-Tree Confident on FY26 Guidance; Focus Turns to US Margin Recovery and £60m Buyback

Management reiterated confidence in meeting full-year 2026 market expectations. Investors will watch second-half US margin recovery, helped by tariff refunds and the benefit of higher marketing investment, plus any further detail on the ongoing £60 million buyback. The next major catalyst will be full-year results and the path of US profitability in 2027. Analyst consensus remains Hold with an average target around 949p.